InvestorsHub Logo
Followers 3
Posts 573
Boards Moderated 0
Alias Born 08/27/2020

Re: None

Thursday, 06/08/2023 7:23:27 AM

Thursday, June 08, 2023 7:23:27 AM

Post# of 44207
Bottom of the recent PR. Coming this year…2023. Anticipating the second wave … hopeful.

“The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2023 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.”